The global Alpha 1 Antitrypsin Deficiency Treatment market was valued at US$ 1860.6 million in 2023 and is anticipated to reach US$ 3425.1 million by 2030, witnessing a CAGR of 9.0% during the forecast period 2024-2030.

Alpha 1 Antitrypsin Deficiency Treatment Market

Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.

Global players of Alpha 1 Antitrypsin Deficiency Treatment include Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, Takeda, Baxter, Grifols, CSL Behring and Kamada Ltd, etc. Top five players occupy for share about 28%. United States is the largest market, with a share about 37%, followed by European Union and China. In terms of product, Augmentation Therapy is the largest segment, with a share over 44%.

This report aims to provide a comprehensive presentation of the global market for Alpha 1 Antitrypsin Deficiency Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Alpha 1 Antitrypsin Deficiency Treatment.

Report Scope

The Alpha 1 Antitrypsin Deficiency Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Alpha 1 Antitrypsin Deficiency Treatment market comprehensively. Regional market sizes, concerning products by Indication, by End Users, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Alpha 1 Antitrypsin Deficiency Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Indication, by End Users, and by regions.

Market Segmentation

Scope of Alpha 1 Antitrypsin Deficiency Treatment Market Report

Report Metric	Details
Report Name	Alpha 1 Antitrypsin Deficiency Treatment Market
Accounted market size in 2023	US$ 1860.6 million
Forecasted market size in 2030	US$ 3425.1 million
CAGR	9.0%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Indication	Augmentation Therapy Cystic Fibrosis(CF) Non-CF Bronchiectasis(NCFB) Diabetes Other
Segment by End Users	COPD Cystic Fibrosis(CF) Non-CF Bronchiectasis(NCFB) Diabetes
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, Takeda, Baxter, Grifols, CSL Behring, Kamada Ltd, Chiesi Pharmaceuticals, Kedrion Group, Vertex Pharmaceuticals, ProMetic Life Sciences
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Indication, by End Users, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Alpha 1 Antitrypsin Deficiency Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Indication, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by End Users, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Alpha 1 Antitrypsin Deficiency Treatment Market growing?

Ans: The Alpha 1 Antitrypsin Deficiency Treatment Market witnessing a CAGR of 9.0% during the forecast period 2024-2030.

What is the Alpha 1 Antitrypsin Deficiency Treatment Market size in 2030?

Ans: The Alpha 1 Antitrypsin Deficiency Treatment Market size in 2030 will be US$ 3425.1 million.

What is the market share of major companies in Alpha 1 Antitrypsin Deficiency Treatment Market?

Ans: Top five players occupy for share about 28%.

What is the Alpha 1 Antitrypsin Deficiency Treatment Market share by region?

Ans: United States is the largest market, with a share about 37%, followed by European Union and China.

Who are the main players in the Alpha 1 Antitrypsin Deficiency Treatment Market report?

Ans: The main players in the Alpha 1 Antitrypsin Deficiency Treatment Market are Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, Takeda, Baxter, Grifols, CSL Behring, Kamada Ltd, Chiesi Pharmaceuticals, Kedrion Group, Vertex Pharmaceuticals, ProMetic Life Sciences

What are the End User segmentation covered in the Alpha 1 Antitrypsin Deficiency Treatment Market report?

Ans: The End users covered in the Alpha 1 Antitrypsin Deficiency Treatment Market report are COPD, Cystic Fibrosis(CF), Non-CF Bronchiectasis(NCFB), Diabetes

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Indication

1.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Indication: 2019 VS 2023 VS 2030

1.2.2 Augmentation Therapy

1.2.3 Cystic Fibrosis(CF)

1.2.4 Non-CF Bronchiectasis(NCFB)

1.2.5 Diabetes

1.2.6 Other

1.3 Market by End Users

1.3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Growth by End Users: 2019 VS 2023 VS 2030

1.3.2 COPD

1.3.3 Cystic Fibrosis(CF)

1.3.4 Non-CF Bronchiectasis(NCFB)

1.3.5 Diabetes

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Perspective (2019-2030)

2.2 Alpha 1 Antitrypsin Deficiency Treatment Growth Trends by Region

2.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Region (2019-2024)

2.2.3 Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Region (2025-2030)

2.3 Alpha 1 Antitrypsin Deficiency Treatment Market Dynamics

2.3.1 Alpha 1 Antitrypsin Deficiency Treatment Industry Trends

2.3.2 Alpha 1 Antitrypsin Deficiency Treatment Market Drivers

2.3.3 Alpha 1 Antitrypsin Deficiency Treatment Market Challenges

2.3.4 Alpha 1 Antitrypsin Deficiency Treatment Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Revenue

3.1.1 Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Revenue (2019-2024)

3.1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Players (2019-2024)

3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Alpha 1 Antitrypsin Deficiency Treatment Revenue

3.4 Global Alpha 1 Antitrypsin Deficiency Treatment Market Concentration Ratio

3.4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Alpha 1 Antitrypsin Deficiency Treatment Revenue in 2023

3.5 Alpha 1 Antitrypsin Deficiency Treatment Key Players Head office and Area Served

3.6 Key Players Alpha 1 Antitrypsin Deficiency Treatment Product Solution and Service

3.7 Date of Enter into Alpha 1 Antitrypsin Deficiency Treatment Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Alpha 1 Antitrypsin Deficiency Treatment Breakdown Data by Indication

4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Indication (2019-2024)

4.2 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Indication (2025-2030)

5 Alpha 1 Antitrypsin Deficiency Treatment Breakdown Data by End Users

5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by End Users (2019-2024)

5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by End Users (2025-2030)

6 North America

6.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2019-2030)

6.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2019-2024)

6.4 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size (2019-2030)

7.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2019-2024)

7.4 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size (2019-2030)

8.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2019-2024)

8.4 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2019-2030)

9.2 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2019-2024)

9.4 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size (2019-2030)

10.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2019-2024)

10.4 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Pfizer

11.1.1 Pfizer Company Detail

11.1.2 Pfizer Business Overview

11.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.1.4 Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

11.1.5 Pfizer Recent Development

11.2 GlaxoSmithKline

11.2.1 GlaxoSmithKline Company Detail

11.2.2 GlaxoSmithKline Business Overview

11.2.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.2.4 GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

11.2.5 GlaxoSmithKline Recent Development

11.3 AstraZeneca

11.3.1 AstraZeneca Company Detail

11.3.2 AstraZeneca Business Overview

11.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.3.4 AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

11.3.5 AstraZeneca Recent Development

11.4 Boehringer Ingelheim

11.4.1 Boehringer Ingelheim Company Detail

11.4.2 Boehringer Ingelheim Business Overview

11.4.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.4.4 Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

11.4.5 Boehringer Ingelheim Recent Development

11.5 Teva Pharmaceutical Industries

11.5.1 Teva Pharmaceutical Industries Company Detail

11.5.2 Teva Pharmaceutical Industries Business Overview

11.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.5.4 Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

11.5.5 Teva Pharmaceutical Industries Recent Development

11.6 Takeda

11.6.1 Takeda Company Detail

11.6.2 Takeda Business Overview

11.6.3 Takeda Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.6.4 Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

11.6.5 Takeda Recent Development

11.7 Baxter

11.7.1 Baxter Company Detail

11.7.2 Baxter Business Overview

11.7.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.7.4 Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

11.7.5 Baxter Recent Development

11.8 Grifols

11.8.1 Grifols Company Detail

11.8.2 Grifols Business Overview

11.8.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.8.4 Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

11.8.5 Grifols Recent Development

11.9 CSL Behring

11.9.1 CSL Behring Company Detail

11.9.2 CSL Behring Business Overview

11.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.9.4 CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

11.9.5 CSL Behring Recent Development

11.10 Kamada Ltd

11.10.1 Kamada Ltd Company Detail

11.10.2 Kamada Ltd Business Overview

11.10.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.10.4 Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

11.10.5 Kamada Ltd Recent Development

11.11 Chiesi Pharmaceuticals

11.11.1 Chiesi Pharmaceuticals Company Detail

11.11.2 Chiesi Pharmaceuticals Business Overview

11.11.3 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.11.4 Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

11.11.5 Chiesi Pharmaceuticals Recent Development

11.12 Kedrion Group

11.12.1 Kedrion Group Company Detail

11.12.2 Kedrion Group Business Overview

11.12.3 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.12.4 Kedrion Group Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

11.12.5 Kedrion Group Recent Development

11.13 Vertex Pharmaceuticals

11.13.1 Vertex Pharmaceuticals Company Detail

11.13.2 Vertex Pharmaceuticals Business Overview

11.13.3 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.13.4 Vertex Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

11.13.5 Vertex Pharmaceuticals Recent Development

11.14 ProMetic Life Sciences

11.14.1 ProMetic Life Sciences Company Detail

11.14.2 ProMetic Life Sciences Business Overview

11.14.3 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.14.4 ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

11.14.5 ProMetic Life Sciences Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Grifols S A

Kamada

Teva Pharmaceutical Industries

Takeda

Baxter

CSL Behring

Chiesi Pharmaceuticals

Kedrion Group

Vertex Pharmaceuticals

ProMetic Life Sciences

List of Tables

Table 1. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Indication (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Augmentation Therapy

Table 3. Key Players of Cystic Fibrosis(CF)

Table 4. Key Players of Non-CF Bronchiectasis(NCFB)

Table 5. Key Players of Diabetes

Table 6. Key Players of Other

Table 7. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth by End Users (US$ Million): 2019 VS 2023 VS 2030

Table 8. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 9. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2019-2024) & (US$ Million)

Table 10. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2019-2024)

Table 11. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 12. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2025-2030)

Table 13. Alpha 1 Antitrypsin Deficiency Treatment Market Trends

Table 14. Alpha 1 Antitrypsin Deficiency Treatment Market Drivers

Table 15. Alpha 1 Antitrypsin Deficiency Treatment Market Challenges

Table 16. Alpha 1 Antitrypsin Deficiency Treatment Market Restraints

Table 17. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Players (2019-2024) & (US$ Million)

Table 18. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Players (2019-2024)

Table 19. Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha 1 Antitrypsin Deficiency Treatment as of 2023)

Table 20. Ranking of Global Top Alpha 1 Antitrypsin Deficiency Treatment Companies by Revenue (US$ Million) in 2023

Table 21. Global 5 Largest Players Market Share by Alpha 1 Antitrypsin Deficiency Treatment Revenue (CR5 and HHI) & (2019-2024)

Table 22. Key Players Headquarters and Area Served

Table 23. Key Players Alpha 1 Antitrypsin Deficiency Treatment Product Solution and Service

Table 24. Date of Enter into Alpha 1 Antitrypsin Deficiency Treatment Market

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2019-2024) & (US$ Million)

Table 27. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication (2019-2024)

Table 28. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Indication (2025-2030) & (US$ Million)

Table 29. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication (2025-2030)

Table 30. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2019-2024) & (US$ Million)

Table 31. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by End Users (2019-2024)

Table 32. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by End Users (2025-2030) & (US$ Million)

Table 33. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by End Users (2025-2030)

Table 34. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 36. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 37. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 38. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 39. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 40. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 41. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2019-2024) & (US$ Million)

Table 42. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2025-2030) & (US$ Million)

Table 43. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 45. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 46. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 47. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 48. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 49. Pfizer Company Detail

Table 50. Pfizer Business Overview

Table 51. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product

Table 52. Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 53. Pfizer Recent Development

Table 54. GlaxoSmithKline Company Detail

Table 55. GlaxoSmithKline Business Overview

Table 56. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product

Table 57. GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 58. GlaxoSmithKline Recent Development

Table 59. AstraZeneca Company Detail

Table 60. AstraZeneca Business Overview

Table 61. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product

Table 62. AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 63. AstraZeneca Recent Development

Table 64. Boehringer Ingelheim Company Detail

Table 65. Boehringer Ingelheim Business Overview

Table 66. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product

Table 67. Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 68. Boehringer Ingelheim Recent Development

Table 69. Teva Pharmaceutical Industries Company Detail

Table 70. Teva Pharmaceutical Industries Business Overview

Table 71. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product

Table 72. Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 73. Teva Pharmaceutical Industries Recent Development

Table 74. Takeda Company Detail

Table 75. Takeda Business Overview

Table 76. Takeda Alpha 1 Antitrypsin Deficiency Treatment Product

Table 77. Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 78. Takeda Recent Development

Table 79. Baxter Company Detail

Table 80. Baxter Business Overview

Table 81. Baxter Alpha 1 Antitrypsin Deficiency Treatment Product

Table 82. Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 83. Baxter Recent Development

Table 84. Grifols Company Detail

Table 85. Grifols Business Overview

Table 86. Grifols Alpha 1 Antitrypsin Deficiency Treatment Product

Table 87. Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 88. Grifols Recent Development

Table 89. CSL Behring Company Detail

Table 90. CSL Behring Business Overview

Table 91. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product

Table 92. CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 93. CSL Behring Recent Development

Table 94. Kamada Ltd Company Detail

Table 95. Kamada Ltd Business Overview

Table 96. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product

Table 97. Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 98. Kamada Ltd Recent Development

Table 99. Chiesi Pharmaceuticals Company Detail

Table 100. Chiesi Pharmaceuticals Business Overview

Table 101. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product

Table 102. Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 103. Chiesi Pharmaceuticals Recent Development

Table 104. Kedrion Group Company Detail

Table 105. Kedrion Group Business Overview

Table 106. Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Product

Table 107. Kedrion Group Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 108. Kedrion Group Recent Development

Table 109. Vertex Pharmaceuticals Company Detail

Table 110. Vertex Pharmaceuticals Business Overview

Table 111. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product

Table 112. Vertex Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 113. Vertex Pharmaceuticals Recent Development

Table 114. ProMetic Life Sciences Company Detail

Table 115. ProMetic Life Sciences Business Overview

Table 116. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product

Table 117. ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 118. ProMetic Life Sciences Recent Development

Table 119. Research Programs/Design for This Report

Table 120. Key Data Information from Secondary Sources

Table 121. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Comparison by Indication (2024-2030) & (US$ Million)

Figure 2. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication: 2023 VS 2030

Figure 3. Augmentation Therapy Features

Figure 4. Cystic Fibrosis(CF) Features

Figure 5. Non-CF Bronchiectasis(NCFB) Features

Figure 6. Diabetes Features

Figure 7. Other Features

Figure 8. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Comparison by End Users (2024-2030) & (US$ Million)

Figure 9. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users: 2023 VS 2030

Figure 10. COPD Case Studies

Figure 11. Cystic Fibrosis(CF) Case Studies

Figure 12. Non-CF Bronchiectasis(NCFB) Case Studies

Figure 13. Diabetes Case Studies

Figure 14. Alpha 1 Antitrypsin Deficiency Treatment Report Years Considered

Figure 15. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 16. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 17. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region: 2023 VS 2030

Figure 18. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Players in 2023

Figure 19. Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha 1 Antitrypsin Deficiency Treatment as of 2023)

Figure 20. The Top 10 and 5 Players Market Share by Alpha 1 Antitrypsin Deficiency Treatment Revenue in 2023

Figure 21. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. North America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2019-2030)

Figure 23. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Canada Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2019-2030)

Figure 27. Germany Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. France Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. U.K. Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Italy Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Russia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Nordic Countries Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2019-2030)

Figure 35. China Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. South Korea Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. India Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Australia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2019-2030)

Figure 43. Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2019-2030)

Figure 47. Turkey Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 49. Pfizer Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

Figure 50. GlaxoSmithKline Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

Figure 51. AstraZeneca Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

Figure 52. Boehringer Ingelheim Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

Figure 53. Teva Pharmaceutical Industries Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

Figure 54. Takeda Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

Figure 55. Baxter Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

Figure 56. Grifols Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

Figure 57. CSL Behring Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

Figure 58. Kamada Ltd Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

Figure 59. Chiesi Pharmaceuticals Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

Figure 60. Kedrion Group Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

Figure 61. Vertex Pharmaceuticals Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

Figure 62. ProMetic Life Sciences Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2019-2024)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Family Asthma Management Product Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-33S10320

Sun Apr 07 00:00:00 UTC 2024

Add to Cart

Global Disposable Oropharyngeal Airway Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-25D8684

Wed Mar 20 00:00:00 UTC 2024

Add to Cart

Global PC-Based Spirometer Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-37U6932

Wed Mar 20 00:00:00 UTC 2024

Add to Cart

Global Respiratory Assistance Devices Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-24S8616

Wed Mar 20 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions